Extended Data Fig. 1: Changes from baseline in the sum of target lesions over time. | Nature Medicine

Extended Data Fig. 1: Changes from baseline in the sum of target lesions over time.

From: Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Extended Data Fig. 1

Spider plot displaying percentage changes from baseline in the sum of target lesions over time in patients from the KL264-01 cohort 3A (A, n = 43), EGFR wildtype subset (B, n = 21) and EGFR-mutant subset (C, n = 22). Five patients in the FAS of cohort 3 (2 belonged to EGFR-wildtype subset, 3 to the EGFR-mutant subset) were unevaluable and are not shown here.

Back to article page